iDayo Selects RIGL as Low Risk Investment

Call Now
800-993-0005

(^DJI) 0

0S&P 500 (^GSPC) 1320.68

1.82NASDAQ Composite (^IXIC) 2839.38

-10.74Russell 2000 (^RUT) 766.57

iDayo™ Stock Selector: RIGL - Rigel Pharmaceuticals

iDayo™ 01/14/08: Rigel Pharmaceuticals (RIGL) - 01/14/08

For the 16 week investment period starting 01/14/08 , the iDayo™ Stock Selector rated Rigel Pharmaceuticals (RIGL) as "Extreme Accumulation" and selected RIGL as a buy for the investment period, identified as iDayo™ 01/14/08.

Company Profile for "Rigel Pharmaceuticals (RIGL)": Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

Google Finance History for RIGL

iDayo, Inc. (including its marketing professionals and staff), is not a registered Investment Advisor or Broker/Dealer, and does not provide investment advice or recommendations. Subscribers to iDayo™ are advised that the information, opinions, and analysis included in our web sites, on our free Educational Conference Calls, or in any other communication are based in good faith on sources believed to be reliable, but no representation or warranty, expressed or implied, is made as to their accuracy, completeness, or correctness.

Past performance is not necessarily indicative of the future performance of stocks posted. None of these postings, the iDayo™ system rating, nor any other information provided on our web sites, on our free Educational Conference Calls, or in any other communication constitutes a recommendation to buy or sell stocks or any other investment. Investing involves the risk of loss and Subscribers are urged to consult with their own independent financial advisors with respect to any investment.